Hormnal suppression for Borderline Ovarian TUmors (BOT) – pro
Contraceptive options and menopause management are frequent clinical issues among women previously treated for a borderline ovarian tumor (BOT).There is no compelling data about effectiveness of BOT. Current or previous oral contraception is associated with a trend towards decreased risk of serous BOT. Mucinous BOT risk is not or slightly decreased by oral contraception. The record does not explain what kind of BOT was in this claimant. Hormonal contraception is thus not contraindicated in women previously treated for a BOT (grade C).
The downside to hormonal therapy is the risk of osteoporosis.
Rousset-Jablonski C, Pautier P, Chopin N. Tumeurs frontières de l’ovaire. Recommandations pour la pratique clinique du CNGOF – Contraception hormonale et THM/THS après tumeur frontière de l’ovaire [Borderline Ovarian Tumours: CNGOFS Guidelines for Clinical Practice - Hormonal Contraception and MHT/HRT after Borderline Ovarian Tumour]. Gynecol Obstet Fertil Senol. 2020 Mar;48(3):337-340.
Văduva CC, Constantinescu C, Ţenovici M, Boldeanu L, Istrate-Ofiţeru AM. Conservative treatment of borderline ovarian tumors: a retrospective study. Rom J Morphol Embryol. 2023 Apr-Jun;64(2):143-150.
OSTER ABSTRACT #5| VOLUME 164, ISSUE 1, P19-20, JANUARY 2022Download Full Issue
Nerlyne Desravines et al, Prescription of hormone replacement therapy in women with surgically induced menopause and borderline ovarian tumors: Should we be doing more? Gyn Oncology OSTER ABSTRACT #5| VOLUME 164, ISSUE 1, P19-20, JANUARY 2022Download Full Issue